NCT01028859View on ClinicalTrials.gov

Safety Study of Increasing Doses of CKD-516 in Patients With Advanced Solid Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

CKD-516 inj

5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 \~ mg/m2; Day 1, Day 8 every 3 weeks

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
collaborator

Seoul National University Hospital

OTHER

lead

Chong Kun Dang Pharmaceutical

INDUSTRY